von Willebrand’s disease: from discovery to therapy – milestones in the last 25 years
Wolfhart Kreuz
DOI: https://doi.org/10.1111/j.1365-2516.2008.01846.x
2008-11-01
Haemophilia
Abstract:In 2006, the haemophilia community commemorated the eightieth anniversary of the first description of von Willebrand s disease (VWD) by Erik von Willebrand and the twenty-fifth anniversary of the introduction of Haemate P, the first effectively virus-inactivated factor VIII (FVIII) plasma product. In this special supplement supported by CSL Behring, key haemophilia clinicians celebrate these momentous achievements in the history of VWD and provide a very informative and interesting summary. The disease, its history, diagnosis, characteristics, treatment and clinical experience, as well as how the development of Haemate P has changed the course of VWD care, are discussed. von Willebrand s disease is an inherited bleeding disorder that is characterized by different qualitative and/or quantitative defects in the von Willebrand factor (VWF), which is a plasma protein that mediates platelet adhesion and aggregation at sites of vascular injury and also binds and stabilizes the blood clotting FVIII in the circulation. Defects in VWF can therefore result in abnormal primary haemostasis, mucocutaneous bleeding, prolonged bleeding time and bleeding manifestations such as haemoarthrosis. Patients with VWD experience variable symptoms ranging from mild effects to potentially devastating haemorrhagic events. The discovery of VWD dates back to the 1920s when Dr Erik von Willebrand first described the bleeding disorder in a 5-year-old girl and subsequently in many members of her family living in the Åland archipelago between Finland and Sweden. It was not until the 1950s that it became clear that human plasma fraction 1-0 could correct both the bleeding deficiency of FVIII and the prolonged bleeding time. But it was only in 1971 that the factor responsible for the prolonged bleeding time was identified by Zimmerman and called VWF. The introduction of immunoassays and molecular techniques demonstrated that patients with moderate and severe VWD have reduced FVIII-related antigen (FVIII:Ag) but a normal FVIII gene on the X chromosome. In many patients, mutations of the VWF gene can be identified on chromosome 12, which result in various forms and multimer patterns of the VWF. The characteristics and role of VWF in primary coagulation are discussed in the presentation by Dr Reininger. VWF circulates together with FVIII in the plasma as a loosely coiled protein complex. Under normal conditions, this complex does not interact with platelets or endothelial cells. However, when vascular injury occurs, VWF binds at the sites of injury by adhering to the exposed subendothelial structures, primarily collagen. Bound VWF can then seize platelets from the flowing blood, especially under high shear conditions, resulting in platelet activation and aggregation and finally thrombus formation. The diagnosis and classification of VWD and its subtypes remains a challenge to the treating physician because of the variability among clinical signs and symptoms and laboratory evaluations. Dr Budde explains that an accurate diagnosis of VWD relies on a stepwise approach of family history, screening procedures, confirmatory tests and tests for final classification. Although our understanding of the disease has progressed and testing procedures have advanced, an accurate diagnosis of the disease requires multiple approaches; no test is accurate enough alone or appropriate for all individuals. In his presentation, Dr Budde describes how the classification of VWD is based on criteria described by the VWF Subcommittee of the International Society of Thrombosis and Haemostasis, which was last updated in 2006. Correspondence: Wolfhart Kreuz, Department of Pediatrics, Hemophilia Comprehensive Care Centre, Clinic III, JohannWolfgang-Goethe University Hospital, 60 596 Frankfurt/Main Germany. Tel.: +49 (0)69 6301 6334; fax: +49 (0)69 6301 6491; e-mail: wolfhart.kreuz@kgu.de